SEC Form 4 · accession 0001193125-26-394456
Trevi Therapeutics, Inc. · TRVI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Heffernan
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:55 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001563880
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 18,421 | $3.04 | A | 24,772 | D | |
| Common StockF2,F1 | Sep 15, 2026 | S | 18,321 | $15.09 | D | 6,451 | D | |
| Common StockF1 | Sep 15, 2026 | S | 100 | $15.88 | D | 6,351 | D | |
| Common Stock | Sep 15, 2026 | M | 21,052 | $3.33 | A | 27,403 | D | |
| Common StockF2,F1 | Sep 15, 2026 | S | 20,952 | $15.09 | D | 6,451 | D | |
| Common StockF1 | Sep 15, 2026 | S | 100 | $15.88 | D | 6,351 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $3.04 | Sep 15, 2026 | M | 18,421 | D | — | — | Common Stock | 18,421 | 0 | D |
| Stock Option (right to buy)F5,F6 | $3.33 | Sep 15, 2026 | M | 21,052 | D | — | — | Common Stock | 21,052 | 0 | D |
Explanation of responses
- F1This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
- F4These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.
- F5These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
- F6These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.